FAO targeting drug | Clinical application | Cancer type | Mechanism of action | References |
---|---|---|---|---|
Metformin | Medicine for type 2 diabetes | Breast cancer | Inhibiting FAO at clinical doses | [117] |
Etomoxir | Retired from phase II clinical trial for diabetes and heart failures | Bladder cancer | Suppressing tumor progression and inducing cell cycle arrest via PPARγ-mediated pathway | [118] |
Malignant glioma | Targeting FAO to reduce energy production and cellular proliferation in glioma cells | [119] | ||
Leukemia | Decreasing leukemia cells proliferation and sensitizing leukemia cells to apoptosis induced by ABT-737 and Nutlin 3a | [120] | ||
Peritoneal metastatic colorectal cancer | Inhibiting cancer-associated fibroblast FAO to decline colorectal cancer metastasis | [121] | ||
Epithelial-derived high-grade serous ovarian cancer | Targeting FAO to promote anoikis and inhibit ovarian cancer progression | [37] | ||
Nasopharyngeal carcinoma | Targeting FAO to sensitize cancer to radiation therapy | [115] | ||
Ranolazine | Medicine for angina pectoris in Europe and United States | Leukemia | Decreasing leukemia cells proliferation and sensitizing leukemia cells to apoptosis induced by ABT-737 and Nutlin 3a | [120] |
Perhexiline | Medicine for angina pectoris in Australia and Asia | Leukemia | Targeting CPT to eliminate chronic lymphocytic leukemia cells in stromal microenvironment | [122] |